Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
Bengaluru & Hyderabad, India; October 8, 2024: Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective
Indian Council of Medical Research Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical Trials
A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens: Union Minister Shri J P Nadda The partnership marks a pivotal step towards establishing India’s
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx
BENGALURU, India–(BUSINESS WIRE)–The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx’s pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research,